



Celgene Europe Limited  
Riverside House  
Riverside Walk  
Windsor  
SL4 1NA  
Tel: +44 (0)1753 240600  
Fax: +44 (0)1753 240656

1 August 2008

Dr Eric Abadie  
Chairman – CHMP  
European Medicines Agency  
7 Westferry Circus  
Canary Wharf, London  
E14 4HB  
United Kingdom

Dear Dr Abadie

**Centralised Marketing Authorisation Application (MAA)  
ORPLATNA<sup>®</sup> (satraplatin) 10 mg and 50 mg, capsules  
EMA Reference: EMA/H/C/000888**

**Withdrawal of MAA**

We would like to inform you that Pharmion Ltd has taken the decision to withdraw the application for Marketing Authorisation of ORPLATNA<sup>®</sup> (satraplatin) 10 mg and 50 mg, capsules intended for use in combination with prednisone or prednisolone, in the treatment of patients with metastatic hormone-refractory prostate cancer (HRPC), who have failed prior chemotherapy.

Celgene acquired Pharmion Ltd (the applicant) in March of 2008.

This withdrawal is based on the following reason:

- The CHMP considers that the data provided do not allow them to conclude a positive benefit-risk balance for ORPLATNA for the treatment of patients with metastatic hormone-refractory prostate cancer (HRPC), who have failed prior chemotherapy.

We reserve the right to make future submissions in this or other therapeutic indications.

We agree for this letter to be published on the EMA website.

Yours sincerely,

Celgene Europe Ltd  
Riverside House  
Riverside Walk  
Windsor  
SL4 1NA  
England